AR060984A1 - Derivados de imidazo[1,5-a]pirido[3,2-e]pirazinas,y su uso en el sistema nervioso central como inhibidores de la fosfodiesterasa 10. - Google Patents
Derivados de imidazo[1,5-a]pirido[3,2-e]pirazinas,y su uso en el sistema nervioso central como inhibidores de la fosfodiesterasa 10.Info
- Publication number
- AR060984A1 AR060984A1 ARP070102308A ARP070102308A AR060984A1 AR 060984 A1 AR060984 A1 AR 060984A1 AR P070102308 A ARP070102308 A AR P070102308A AR P070102308 A ARP070102308 A AR P070102308A AR 060984 A1 AR060984 A1 AR 060984A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halo
- polysubstituted
- optionally mono
- cyclic radical
- Prior art date
Links
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 title 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 title 1
- 210000003169 central nervous system Anatomy 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 18
- 125000005843 halogen group Chemical group 0.000 abstract 16
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 abstract 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 4
- -1 cyclic radical Chemical class 0.000 abstract 4
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 2
- 150000001204 N-oxides Chemical class 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 1
- 101100516554 Caenorhabditis elegans nhr-5 gene Chemical group 0.000 abstract 1
- 101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 230000007278 cognition impairment Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Polymers 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Composiciones farmacéuticas que los contienen. Métodos de preparacion y usos para el tratamiento de trastornos neurologicos y psiquiátricos, por ejemplo psicosis y trastornos que comprenden déficits cognitivos como síntomas. Reivindicacion 1: Compuestos caracterizados porque tienen la formula (2) donde R1 y R2 se seleccionan en forma independiente de H, un radical cíclico, alquilo C1-8 o cicloalquilo C3-8, opcionalmente mono- o polisustituido con halo, OH, O-alquilo C1-3 y/o un radical cíclico, alquenilo C2-8 o cicloalquenilo C3-8, opcionalmente mono- o polisustituido con halo, OH, O-alquilo C1-3 y/o un radical cíclico, alquinilo C2-8, opcionalmente mono- o polisustituido con halo, OH, O-alquilo C1-3 y/o un radical cíclico, un heterociclo saturado, mono-insaturado o poli-insaturado con 5 a 15 átomos anulares, opcionalmente mono- o polisustituido con halo, amino, alquilamino C1-3, dialquilamino C1-3, nitro, alquilo C1-3 y/o O-alquilo C1-3O-C1-3 alquilo y fenilo, opcionalmente mono- o polisustituido con halo, amino, alquilamino C1-3, di-alquilamino C1-3, nitro, alquilo C1-3, O-alquilo C1-3 y/o un radical cíclico; R3 es NH2, NHR5 o NR5R6; donde R5 y R6 se seleccionan en forma independiente de un radical cíclico, alquilo C1-5, opcionalmente mono- o polisustituido con halo, OH, O-alquilo C1-3 y/o un radical cíclico, aril-alquilo C1-5 donde arilo es fenilo, opcionalmente mono- o polisustituido con halo, nitro, alquilo C1-3 y/u O-alquilo C1-3, - (C=O)alquilo C1-5 opcionalmente mono- o polisustituido con halo, OH, O-alquilo C1-3 y/o un radical cíclico, o NR5R6 forman en conjunto un anillo saturado o no saturado de cinco o seis miembros que puede contener hasta 3 heteroátomos, con preferencia N que Incluye N-oxido, S y O, opcionalmente mono- o polisustituido con halo, alquilo C1-3, O-alquilo C1-3 y/o arilalquilo C1-5, donde arilo es fenilo, opcionalmente mono- o polisustituido con halo, amino, alquilamino C1-3, di-alquilamino C1-3, nitro, alquilo C1-3, O-alquilo C1-3 y/o un radical cíclico, R4 se selecciona de H, halo un radical cíclico, R7, OH u OR7, NH(C=O)-alquilo C1-3, opcionalmente mono- o polisustituido con halo, OH, O-alquilo C1-3 y/o un radical cíclico o NH2, NHR7 o NR7R8, donde R7 y R8 se seleccionan en forma independiente de un radical cíclico, alquilo C1-6 o cicloalquilo C3-6, opcionalmente mono- o polisustituido con halo, OH, O-alquilo C1-3 y/o un radical cíclico, aril-alquilo C1-5 donde arilo es fenilo, opcionalmente mono- o polisustituido con halo, amino, alquilamino C1-3, di-alquilamino C1-3, nitro, alquilo C1-3, O-alquilo C1-3 y/o un radical cíclico, NR7R8 forman en conjunto un anillo saturado o no saturado de cinco, seis o siete miembros que puede contener hasta 3 heteroátomos, con preferencia N que incluye N-oxido, S y O, opcionalmente mono- o polisustituido con halo, cicloalquilo C1-3, alquilo C3-6, O-alquilo C1-3 y/o aril-alquilo C1-5, donde arilo es fenilo, opcionalmente mono- o polisustituido con halo, amino, alquilamino C1-3, di-alquilamino C1-3, nitro, alquilo C1-3, O-alquilo C1-3 y/o un radical cíclico, o sales aceptables para uso farmacéutico y derivados de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80925106P | 2006-05-30 | 2006-05-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR060984A1 true AR060984A1 (es) | 2008-07-23 |
Family
ID=38441601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102308A AR060984A1 (es) | 2006-05-30 | 2007-05-29 | Derivados de imidazo[1,5-a]pirido[3,2-e]pirazinas,y su uso en el sistema nervioso central como inhibidores de la fosfodiesterasa 10. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20070299079A1 (es) |
| EP (1) | EP2021341A1 (es) |
| JP (1) | JP2009538852A (es) |
| CN (1) | CN101448829A (es) |
| AR (1) | AR060984A1 (es) |
| AU (1) | AU2007267391A1 (es) |
| BR (1) | BRPI0711857A2 (es) |
| CA (1) | CA2653412A1 (es) |
| CL (1) | CL2007001555A1 (es) |
| MX (1) | MX2008015308A (es) |
| PE (1) | PE20080266A1 (es) |
| TW (1) | TW200815436A (es) |
| WO (1) | WO2007137819A1 (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8299080B2 (en) * | 2006-12-13 | 2012-10-30 | Aska Pharmaceutical Co., Ltd. | Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor |
| RU2010126622A (ru) * | 2007-11-30 | 2012-01-10 | УАЙТ ЭлЭлСи (US) | Конденсированные с арилом и гетероарилом имидазо[1, 5-а]пиразины в качестве ингибиторов фосфодиэстеразы 10 |
| US20090143392A1 (en) * | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Methods of Treating Obesity and Metabolic Disorders |
| WO2009070583A1 (en) * | 2007-11-30 | 2009-06-04 | Wyeth | Pyrido[3,2-e]pyrazines, process for preparing the same, and their use as inhibitors of phosphodiesterase 10 |
| US20100120763A1 (en) * | 2008-11-07 | 2010-05-13 | Wyeth | Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases |
| EP2576540B1 (en) * | 2010-05-26 | 2019-09-04 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| DE102010042833B4 (de) | 2010-10-22 | 2018-11-08 | Helmholtz-Zentrum Dresden - Rossendorf E.V. | Neue Halogenalkoxychinazoline, deren Herstellung und Verwendung |
| US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
| CN103476757A (zh) | 2011-02-18 | 2013-12-25 | 阿勒根公司 | 作为磷酸二酯酶10(pde10a)的抑制剂的取代的6,7-二烷氧基-3-异喹啉醇衍生物 |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| US9056863B2 (en) * | 2011-09-09 | 2015-06-16 | H. Lundbeck A/S | Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof |
| EP2906562B1 (en) | 2011-10-10 | 2016-10-05 | H. Lundbeck A/S | Pde9i with imidazo pyrazinone backbone |
| US20130116241A1 (en) | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
| RU2014123352A (ru) | 2011-11-09 | 2015-12-20 | Эббви Дойчланд Гмбх Унд Ко. Кг | Гетероциклические карбоксамиды, полезные в качестве ингибиторов фосфодиэстеразы типа 10а |
| AU2013213603B2 (en) | 2012-01-26 | 2017-02-02 | H. Lundbeck A/S | PDE9 inhibitors with imidazo triazinone backbone |
| PE20142258A1 (es) | 2012-04-25 | 2015-01-15 | Takeda Pharmaceutical | Compuesto heterociclico nitrogenado |
| CN104583210B (zh) | 2012-06-19 | 2018-06-01 | 桑诺维恩药品公司 | 杂芳基化合物及其使用方法 |
| EP2873669A4 (en) | 2012-07-13 | 2015-11-25 | Takeda Pharmaceutical | HETEROCYCLIC CONNECTION |
| US20140045856A1 (en) * | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
| US9464085B2 (en) | 2012-08-17 | 2016-10-11 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
| MX2015003419A (es) | 2012-09-17 | 2015-09-23 | Abbvie Deutschland | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a. |
| WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| US9790203B2 (en) | 2012-11-26 | 2017-10-17 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| US9200005B2 (en) | 2013-03-13 | 2015-12-01 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
| AU2014230745A1 (en) | 2013-03-14 | 2015-09-03 | AbbVie Deutschland GmbH & Co. KG | Novel inhibitor compounds of phosphodiesterase type 10A |
| JP6280912B2 (ja) | 2013-03-14 | 2018-02-14 | 武田薬品工業株式会社 | 複素環化合物 |
| ES2950424T3 (es) | 2013-07-03 | 2023-10-09 | Takeda Pharmaceuticals Co | Compuesto de amida |
| US10053468B2 (en) | 2013-07-03 | 2018-08-21 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
| CN103980281B (zh) * | 2014-05-27 | 2016-06-08 | 天津市斯芬克司药物研发有限公司 | 一种咪唑吡嗪化合物及其制备方法 |
| EP3303339B1 (en) | 2015-07-07 | 2021-01-13 | H. Lundbeck A/S | Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases |
| KR20210014662A (ko) | 2018-05-25 | 2021-02-09 | 이마라 인크. | 6-[(3S,4S)-4-메틸-1-(피리미딘-2-일메틸)피롤리딘-3-일]-3-테트라히드로피란-4-일-7H-이미다조[1,5-a]피라진-8-온의 일수화물 및 결정형 |
| EP3843737A4 (en) | 2018-08-31 | 2022-06-01 | Imara Inc. | PDE9 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE |
| US20210379061A1 (en) | 2018-09-28 | 2021-12-09 | Takeda Pharmaceutical Company Limited | Balipodect for treating or preventing autism spectrum disorders |
| CN114524808B (zh) * | 2022-02-21 | 2023-10-24 | 深圳市儿童医院 | 一种吡唑衍生物及其作为pde10抑制剂的用途 |
| CN114524806B (zh) * | 2022-02-22 | 2024-09-03 | 深圳市儿童医院 | 一种三氮唑衍生物及其作为pde10抑制剂的用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999045009A1 (en) * | 1998-03-04 | 1999-09-10 | Bristol-Myers Squibb Company | Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors |
| JPH11292878A (ja) * | 1998-04-09 | 1999-10-26 | Yamanouchi Pharmaceut Co Ltd | イミダゾナフチリジン誘導体 |
| IL149106A0 (en) * | 2001-04-20 | 2002-11-10 | Pfizer Prod Inc | Therapeutic use of selective pde10 inhibitors |
| US20030032579A1 (en) * | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| TW200817400A (en) * | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
-
2007
- 2007-05-18 TW TW096117904A patent/TW200815436A/zh unknown
- 2007-05-24 US US11/753,260 patent/US20070299079A1/en not_active Abandoned
- 2007-05-29 CN CNA2007800178341A patent/CN101448829A/zh active Pending
- 2007-05-29 AR ARP070102308A patent/AR060984A1/es unknown
- 2007-05-29 JP JP2009512481A patent/JP2009538852A/ja active Pending
- 2007-05-29 WO PCT/EP2007/004747 patent/WO2007137819A1/en active Application Filing
- 2007-05-29 EP EP07725638A patent/EP2021341A1/en not_active Withdrawn
- 2007-05-29 AU AU2007267391A patent/AU2007267391A1/en not_active Abandoned
- 2007-05-29 BR BRPI0711857-0A patent/BRPI0711857A2/pt not_active IP Right Cessation
- 2007-05-29 MX MX2008015308A patent/MX2008015308A/es not_active Application Discontinuation
- 2007-05-29 CA CA002653412A patent/CA2653412A1/en not_active Abandoned
- 2007-05-30 CL CL2007001555A patent/CL2007001555A1/es unknown
- 2007-05-30 PE PE2007000675A patent/PE20080266A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CL2007001555A1 (es) | 2008-01-18 |
| US20070299079A1 (en) | 2007-12-27 |
| TW200815436A (en) | 2008-04-01 |
| CN101448829A (zh) | 2009-06-03 |
| EP2021341A1 (en) | 2009-02-11 |
| PE20080266A1 (es) | 2008-04-10 |
| BRPI0711857A2 (pt) | 2011-12-13 |
| MX2008015308A (es) | 2008-12-12 |
| AU2007267391A1 (en) | 2007-12-06 |
| CA2653412A1 (en) | 2007-12-06 |
| WO2007137819A1 (en) | 2007-12-06 |
| JP2009538852A (ja) | 2009-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR060984A1 (es) | Derivados de imidazo[1,5-a]pirido[3,2-e]pirazinas,y su uso en el sistema nervioso central como inhibidores de la fosfodiesterasa 10. | |
| AR061206A1 (es) | Pirido[3,2-e]pirazinas, su uso como inhibidores de la fosfodiesterasa 10, y procesos para prepararlas | |
| AR069510A1 (es) | Arilo y heteroarilo imidazo[1,5-a]pirazinas fusionadas como inhibidores de la fosfodiesterasa 10 | |
| CO6602133A2 (es) | Derivados de i,idazo(1,2-a)pirazina y su uso para la prevencion o tratamiento de trastornos y enfermedades neurologicas, siquiatricas y metabolicas | |
| CO2018005163A2 (es) | Compuesto de [1,2,4]triazolo[1,5-a]pirimidin-7-ilo | |
| UY29838A1 (es) | Derivados sustituidos de 4,5,6,7-tetrahidropirrolo(3,2,c)piridin-4-ona y de 4,5-tetrahidropirrolo(3,2,c)piridin-4-ona, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones | |
| AR080785A1 (es) | Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros. | |
| MX381326B (es) | Derivados de 7h-imidazo[1-5-a]pirazin-8-ona como inhibidores de la fosfodiesterasa 9(pde9); y el uso de los mismos en el tratamiento de trastornos neurodegenerativos | |
| CO6531468A2 (es) | Derivados de imidazo[1,2-b] piridazina y su uso como inhibidores de pde 10 | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| CL2011002839A1 (es) | Compuestos derivados de 1,2,4-triazolo[4,3-a]piridina, moduladores alostéricos positivos de receptores mglur2; composición farmacéutica y su proceso de preparacion; combinación farmaceutica; y su uso en el tratamiento o prevencion de un trastorno del sistema nervioso central tal como ansiedad y esquizofrenia, entre otros. | |
| CL2009001152A1 (es) | Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. | |
| PE20170128A1 (es) | Compuestos para tratar atrofia muscular espinal | |
| PE20170403A1 (es) | COMPUESTOS DE IMIDAZO[4,5-c]QUINOLIN-2-ONA Y SU USO PARA TRATAR CANCER | |
| PE20080263A1 (es) | Compuestos de pirrolo-pirimidina y sus usos | |
| AR043155A1 (es) | Derivados sustituidos de hexahidro-pirazino[1,2-a] pirimidin-4,7-diona, procedimientos para su preparacion y su uso como medicamentos | |
| AR065015A1 (es) | Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer | |
| EA200970510A1 (ru) | Гетеромоноциклическое соединение и его применение | |
| AR043154A1 (es) | Derivados sustituidos con nitrogeno de hexahidro-pirazino[1,2-a] pirimidin-4,7-diona, procedimientos para su preparacion y su uso como medicamentos | |
| MX2016015874A (es) | Derivados radiomarcadores de un compuesto de 2-amino-6-fluoro-n-[5 -fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida util como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparacion de tal compuesto y diferentes formas solidas del mismo. | |
| AR097431A1 (es) | Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim | |
| CL2008003577A1 (es) | Compuestos derivados de imidazo[1,5-a] pirido[3,2-e]pirazina, 2, 6, 7, 9 tetrasustituidos; inhibidores de fosfodiesterasa 10; procedimiento de preparación; composición farmacéutica que comprende a dichos compuestos; y su uso para tratar enfermedades relacionadas con el sistema nervioso central, obesidad y trastornos del metabolismo. | |
| PE20110584A1 (es) | DERIVADOS DE IMIDAZO[1,2-a]PIRIMIDINA COMO INHIBIDORES DE MET, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU PROCEDIMIENTO DE PREPARACION | |
| PE20160125A1 (es) | Pirazolpiridinas sustituidas | |
| EA201991094A1 (ru) | СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |